Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Treatment of Insomnia in Palliative Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically verified malignant disease~2. Presence of metastatic / disseminated disease~3. Presence of insomnia syndrome defined as:~   1. Self-reported difficulty with initiating sleep (greater than 30 minutes to sleep onset) and/or difficulty maintaining sleep (greater than 30 minutes nocturnal waking time); and~  2. Sleep difficulty at least 3 nights per week; and~  3. Sleep difficulty that causes significant impairment of daytime functioning (The patient will be asked if sleep difficulty result in altered daytime function i.e. feeling tired, lack of energy)~4. Able to comply with all study procedures~5. Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.~Exclusion Criteria:~1. On-going treatment or previous treatment (within last 4 weeks) for more than consecutive 3 days with medications given for insomnia~2. Adverse reactions to zopiclone~3. History of substance abuse~4. Concomitant use of rifampicin and erythromycin~5. Any other contraindication listed on the summary of product characteristics of the investigated medicinal product:~   1. Myasthenia gravis~  2. An established diagnosis of Severe impairment of respiratory function~  3. An established diagnosis of Severe hepatic insufficiency.(Child-Pugh grade B or C)~  4. An established diagnosis of sleep apnea~  5. Known hypersensitivity to the drug or to any component in its formulation: Lactose monohydrate, Calcium hydrogen phosphate, Maize starch, Croscarmellose sodium, Magnesium stearate, Titanium dioxide (E 171), Hypromellose, Iron oxide yellow/Iron oxide red (E 172) and Macrogol~6. Unfit for participation for any reason as judged by the investigator~7. Pregnancy or lactation~8. Women of reproductive age not willing or unable to employ an effective method of contraception (sterilization, using IUD or oral contraception)~9. Scheduled surgery within the next week~10. In the need of change in scheduled opioid dose at baseline (study visit 1)~11. Scheduled intravenous administration of chemotherapy during the study period (from baseline to day 8) or intravenous administration of chemotherapy during the last week~12. Change in corticosteroid dose last week before baseline or planned dose change in corticosteroid dose within 7 days from baseline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zopiclone (Type: ACTIVE_COMPARATOR): Zopiclone six nights
- Placebo (Type: PLACEBO_COMPARATOR): Placebo six nights

Based on this trial design, predict the completion outcome and termination type (if applicable).